Cargando…
Current trials in erythropoietic protoporphyria: are placebo controls ethical?
A new active substance called “dersimelagon” (MT-7117) is being tested as an alternative treatment option for Erythropoietic protoporphyria (EPP). At the moment, dersimelagon is being tested both in the US and in Europe in a phase III placebo-controlled RCT. However, given the availability of an alr...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580501/ https://www.ncbi.nlm.nih.gov/pubmed/37845740 http://dx.doi.org/10.1186/s13023-023-02941-w |